Management of Insomnia and Anxiety After Cardiac Surgery

1. Guideline Recommendations Against Trazodone

The American Academy of Sleep Medicine advises that trazodone should not be used for insomnia, and the American Heart Association recommends cognitive‑behavioral therapy for insomnia (CBT‑I) first, reserving sedating antidepressants such as mirtazapine or melatonin‑receptor agonists—not trazodone—when medication is required. 1

In older adults, trazodone yields only minimal, clinically insignificant improvements: about a 10‑minute reduction in sleep‑onset latency and an 8‑minute reduction in wake after sleep onset, with no measurable enhancement in subjective sleep quality. 2
A single high‑quality trial in seniors reported adverse events in 75 % of patients receiving trazodone versus 65 % on placebo; the most common were headache (30 %) and somnolence (23 %). 2
The guideline task force concluded that the harms of trazodone outweigh its modest benefits, despite its frequent clinical use. 2

CBT‑I is the recommended first‑line treatment for all adults with insomnia, including post‑cardiac‑surgery patients, providing superior long‑term efficacy and sustained benefits after discontinuation. 1
CBT‑I incorporates stimulus control, sleep restriction, relaxation techniques, and cognitive restructuring and can be delivered in person, by telephone, or via web‑based modules. 2
The American Heart Association specifically mandates CBT‑I before any pharmacologic intervention for cardiovascular patients with insomnia. 1

Mirtazapine 7.5–15 mg taken at bedtime is the preferred medication for post‑cardiac‑surgery patients with co‑existing anxiety and insomnia. 1
The American Heart Association notes that mirtazapine is safe in cardiovascular disease and additionally promotes appetite and sleep without the cardiac risks associated with trazodone. 1
Mirtazapine should be administered nightly on a scheduled basis (not PRN) to maintain consistent therapeutic levels. 2

Low‑dose doxepin 3–6 mg reduces wake after sleep onset by approximately 22–23 minutes, has minimal anticholinergic activity at hypnotic doses, and carries no abuse potential. 2
Ramelteon 8 mg, a melatonin‑receptor agonist, has no cardiovascular risks, no abuse potential, and no withdrawal symptoms. 1

Zolpidem 5 mg (reduced dose for patients ≥ 65 years) shortens sleep‑onset latency by roughly 25 minutes. 2
Zaleplon 5 mg (reduced dose for elderly) has an ultra‑short half‑life, producing minimal residual sedation. 2

Patients should be reassessed after 1–2 weeks to evaluate sleep outcomes, daytime functioning, and adverse effects such as morning sedation, cognitive impairment, or cardiac symptoms. 2
The lowest effective dose for the shortest necessary duration should be used, with ongoing CBT‑I to facilitate eventual tapering of medication. 2
Combining multiple sedating agents should be avoided because it markedly increases the risk of respiratory depression, cognitive impairment, and falls. 2

Sertraline is the preferred selective serotonin reuptake inhibitor for anxiety in this population, owing to its lower propensity for QTc prolongation compared with citalopram or escitalopram. 1
Monoamine oxidase inhibitors and tricyclic antidepressants should be avoided due to significant cardiovascular adverse effects, including hypertension, hypotension, and arrhythmias. 1
Clinicians should screen for and address underlying contributors to insomnia—such as postoperative pain, medication side effects (e.g., β‑blockers, diuretics), and sleep‑disordered breathing, which are common after cardiac surgery. 1